The April 2024 workshop focused on strengthening grant applications for submission in 2024 and beyond. This workshop included:
- presentations on current grant opportunities, including what’s new and helpful for grant-writers
- peer input and review on grants for submission in 2023 and beyond.
Workshop Downloads
Presentations
- Overview of GCCTI and achievements to date (Katrin Sjoquist)
- Funding updates: what’s new and helpful for grant-writers
- MRFF (Jordane Malaterre)
- NHMRC – Clinical Trials and Cohort Studies (Wee-Ming Boon & Sarah Hazell)
- Cancer Australia – Priority-driven Collaborative Cancer Research Scheme and Support for Cancer Clinical Trials (Adam Lambert)
- Progress updates from previous presented concepts
- REZOLV3R – Intraperitoneal bevacizumab for recurrent, malignant ascites (Katrin Sjoquist)
- GeneScreen 5-FU – Genotype-guided personalized fluoropyrimidine and irinotecan dosing: cost-effectiveness (Steve Ackland)
- A randomised controlled trial investigating Ventilation Imaging to improve the quality of life for patients with Lung cancer radiation therapy patients (VITaL) (Paul Keall)
- Updates on Omico, MoST and PrOSPeCT (David Thomas)
- Trial concepts for peer input
- Opioid Pharmacogenomics Registry Trial for Cancer Pain (OPPtiC-2) (Aaron K Wong)
- Addition of stereotactic radiosurgery to molecularly targeted therapies in driver mutation-positive non-small cell lung cancer with persistent or progressive brain metastases: a randomized basked trial (OUTRUN-P2) (Yu Yang Soon)
- Neoadjuvant radiotherapy: Improving responses to neoadjuvant chemo/immunotherapy in resectable NSCLC with high precision radiotherapy (Fiona Hegi-Johnson)
- Investigation of microbiome genomic signature associated with immune-related adverse event and response in patients with advanced cancer treated with anti-cancer immune checkpoint inhibitors (Sonia Yip)
Workshop Report
The workshop report includes a summary of presentations and discussion from the day, including the workshop evaluation. This will be available shortly.